Skip to Content

Carbaglu FDA Approval History

FDA Approved: Yes (First approved March 18, 2010)
Brand name: Carbaglu
Generic name: carglumic acid
Dosage form: Tablets
Company: Orphan Europe
Treatment for: Hyperammonemia

Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated for the treatment of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).

Development Timeline for Carbaglu

DateArticle
Mar 18, 2010ApprovalFDA Approves Carbaglu to Treat Condition That Causes Elevated Ammonia Levels

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.